// App-Quantinova.ai

4573 : Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.

Researchers

Presenter

  • Leonard Joseph Appleman

Principal Investigators

  • Daniel Paul Normolle

  • Theodore F. Logan

  • Paul Monk

  • Thomas Olencki

  • David F. McDermott

  • Marc S. Ernstoff

  • Jodi Kathleen Maranchie

  • Rahul Atul Parikh

  • David Friedland

  • Herbert Zeh

  • Xiaoyan Liang

  • Lisa Helene Butterfield

  • Michael T. Lotze

Medical Centers

  • University of Pittsburgh, Pittsburgh, PA

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • The Ohio State Univerisity, Columbus, OH

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Cleveland Clinic, Cleveland, OH

  • University of Kansas, Kansas City, KS

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Cytokine

  • Interleukin-2

Drug/Treatment

  • Hydroxychloroquine

  • Aldesleukin

Outcome

  • N/A

Study Design

  • Multinational

  • Dose Escalation

Phase

  • II

Study Id's

  • NCT01550367

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved